The genomic amplification, rearrangements, and increased PVT1 expression exhibited oncogenic and epigenetic regulation effects on breast cancer (25), prostate cancer (26), and acute myeloid leukemia (27). The gene discussed is PVT1; the disease is prostate cancer.